VAX-ID Now Cleared for Commercialisation in the UK
Antwerp, Belgium – September 10, 2025 – Idevax, a pioneering medical device company specialising in innovative skin drug delivery solutions, today announced that its flagship product, VAX-ID®, has been successfully registered with the UK Medicines and Healthcare produce Regulatory Agency (MHRA). This regulation, completed with the support of Idevax’s UK Responsible Person, QbD Group, confirms that VAX-ID® is now listed on the official Public Access Registeration Database PARD (MHRA database of approved medical devices).
“We’re incredibly proud of our team for reaching this significant regulatory milestone—securing MHRA clearance for VAX-ID and officially entering the UK market. This achievement marks a major step forward in expanding access to our innovative intradermal delivery technology. We’re excited to roll out VAX-ID across a wide range of applications, from preventive and therapeutic vaccines to TB skin testing and dermatology, helping improve patient outcomes and healthcare delivery.”
— Vanessa Vankerckhoven, CEO & Founder of Idevax
This milestone enables the commercialisation and distribution of VAX-ID® in the United Kingdom, ensuring compliance with the country’s post-Brexit regulatory framework. It builds on VAX-ID®’s prior CE marking as a Class IIa medical device, under the European Medical Device Regulations (MDR).
For more information about VAX-ID® and Idevax, please visit Idevax’s website.
Contact:
Vanessa Vankerckhoven – Founder & CEO –Vanessa.vankerckhoven@idevax.com – +32486761885
About Idevax
Idevax is a pioneering medical device company based in Antwerp and Wijnegem, Flanders, Belgium. Founded in 2020 by Vanessa Vankerckhoven and Koen Beyers, Idevax is an ISO13485-certified company dedicated to developing, producing, and commercialising innovative precision drug delivery devices. The company’s mission is to enable reliable skin drug delivery and enhance patient comfort through cutting-edge solutions and commitment to excellence. The VAX-ID® device platform has CE mark to deliver medications and vaccines intradermally. The devices are safe, accurate, easy to use by healthcare professionals and offer patient comfort. They can improve vaccine effectiveness and offer dose-sparing potential.
For more information or if you are interested in partnering with us, check out our website or contact us. Follow us on LinkedIn.
